Extramammary Paget Disease (EMPD) — a rare intraepithelial adenocarcinoma arising in skin bearing apocrine glands, most commonly in the anogenital region (vulva accounting for the majority of female cases, followed by the perianal region in both sexes, the scrotum and penile shaft in males, and less commonly the axilla, umbilicus, eyelid, and external auditory canal), presenting as a well-demarcated, erythematous, eczematoid, weeping, or crusted plaque that is characteristically pruritic and slowly progressive, masquerading clinically as inflammatory dermatoses including psoriasis, eczema, contact dermatitis, and intertrigo for months to years before the diagnosis of malignancy is established — represents one of the most diagnostically deceptive malignancies in gynecologic, dermatologic, and anorectal oncology, where the inflammatory clinical appearance and indolent growth pattern produce average diagnostic delays of three to five years from symptom onset to histopathologic diagnosis, during which interval the intraepithelial tumor may have expanded substantially across the anogenital skin surface before detection. EMPD is classified by its relationship to an underlying visceral malignancy: primary EMPD arises de novo from the intraepithelial apocrine gland cells of the skin and may remain in situ or invade the dermis (invasive EMPD) or extend to regional lymph nodes and distant sites; secondary EMPD represents pagetoid spread of an adjacent visceral adenocarcinoma — most commonly colorectal carcinoma for perianal EMPD, urothelial carcinoma for penile and perineal EMPD, and gynecologic carcinomas for vulvar EMPD — where tumor cells from the underlying visceral primary colonize the overlying skin epithelium in a pattern that is histologically indistinguishable from primary EMPD on hematoxylin and eosin staining but can be distinguished using an immunohistochemical panel including CK20 (positive in secondary colorectal EMPD), GATA3 (positive in secondary urothelial EMPD), CK7, GCDFP-15, and androgen receptor (positive in primary EMPD). This classification distinction is of the highest clinical importance because secondary EMPD demands identification and treatment of the underlying visceral malignancy rather than (or in addition to) treatment of the cutaneous Paget disease itself, making immunohistochemical panel workup and colonoscopy or cystoscopy to exclude a synchronous visceral primary a standard component of the initial EMPD workup. The molecular profile of primary EMPD includes HER2 overexpression/amplification in approximately 50–70% of invasive EMPD cases (substantially higher than the 15–20% HER2-positive rate in breast cancer), with HER2-directed therapy (trastuzumab, pertuzumab, trastuzumab deruxtecan) representing the most molecularly rational targeted approach in advanced or invasive primary EMPD and an area of active clinical investigation; TP53 mutations, CDKN2A loss, and PIK3CA mutations are additionally identified across EMPD molecular profiles. Microsatellite instability is uncommon in primary EMPD but should be assessed given the implication for pembrolizumab eligibility. Treatment of localized EMPD centers on wide local excision with negative margins — complicated by the microscopic extent of intraepithelial disease beyond the visible tumor edge, explaining the 30–50% local recurrence rate after standard wide excision, and driving the use of Mohs micrographic surgery (particularly with immunostaining for CK7, GCDFP-15, and CAM5.2 on frozen sections to identify scattered Paget cells at margins), imiquimod topical immunotherapy for in situ disease in patients who cannot tolerate or prefer to avoid surgery, photodynamic therapy for intraepithelial EMPD, and radiation therapy (as definitive treatment in non-surgical candidates or as adjuvant therapy for invasive disease with high-risk features). Trastuzumab-based therapy for HER2-positive invasive EMPD represents an emerging standard for advanced disease, and clinical trial enrollment should be offered. The multidisciplinary team includes gynecologic oncologists managing vulvar EMPD resection and reconstruction, colorectal surgeons managing perianal EMPD resection and associated colorectal malignancy evaluation, urologic oncologists managing penile and perineal EMPD, dermatologic and cutaneous surgical oncologists managing EMPD at extragenital sites, Mohs surgeons performing complete margin assessment for anogenital EMPD, dermatopathologists performing the EMPD immunohistochemical workup distinguishing primary from secondary EMPD, radiation oncologists managing definitive and adjuvant radiation for non-surgical candidates and invasive disease, and medical oncologists managing HER2-directed therapy, pembrolizumab, and investigational systemic therapies for advanced and metastatic EMPD.
Extramammary Paget disease technology platforms — whether supporting gynecologic oncology platforms coordinating vulvar EMPD wide excision and vulvar reconstruction (where functional and anatomic outcomes of vulvar surgery include sexual function, urinary continence, and wound healing in the anogenital region that demand careful reconstructive surgical planning and post-operative rehabilitation), colorectal surgery and anorectal oncology platforms managing perianal EMPD resection and the colonoscopy and colorectal cancer exclusion workup that the secondary EMPD pathway requires, urologic oncology platforms managing penile and perineal EMPD resection and cystoscopy-based urothelial carcinoma exclusion, Mohs micrographic surgery platforms coordinating complete peripheral and deep margin assessment with immunohistochemical EMPD-marker frozen sections (CK7, GCDFP-15, androgen receptor, CAM5.2) for anogenital EMPD where the invisible intraepithelial disease extent makes standard excision inadequate, dermatopathology platforms managing the immunohistochemical panel workup distinguishing primary from secondary EMPD and molecular testing for HER2 amplification by FISH and microsatellite instability assessment for systemic therapy eligibility determination, radiation oncology platforms delivering definitive external beam or brachytherapy to the anogenital region in non-surgical candidates and adjuvant radiation for invasive EMPD with lymph node involvement, medical oncology platforms managing trastuzumab-based HER2-directed therapy (trastuzumab, pertuzumab, trastuzumab deruxtecan, lapatinib) and pembrolizumab immunotherapy for advanced EMPD with PD-L1 expression or MSI-H status, imiquimod topical therapy monitoring platforms for patients undergoing non-surgical management of in situ EMPD, dermatology and gynecology surveillance platforms managing the lifetime skin surveillance required for a disease with high local recurrence rates and the potential for invasive transformation of recurrent in situ disease, and patient portals supporting patients navigating the psychological complexity of anogenital malignancy management, sexual health rehabilitation, and long-term skin surveillance — must maintain the availability and performance standards that EMPD's diagnostic classification complexity, visceral malignancy exclusion workup requirements, HER2-directed therapy management, and Mohs surgery margin assessment demands. This guide explains why extramammary Paget disease tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the immunohistochemical diagnostic precision, Mohs surgery coordination, HER2-directed therapy management complexity, and visceral malignancy exclusion demands of modern EMPD care.
Why Extramammary Paget Disease Tech Platforms Require Specialized Monitoring Attention
EMPD management is defined by immunohistochemical panel workup distinguishing primary from secondary EMPD, visceral malignancy exclusion workup (colonoscopy, cystoscopy, gynecologic evaluation), Mohs micrographic surgery with immunostained frozen sections for complete margin assessment of intraepithelial disease with invisible extent, HER2 FISH amplification testing for HER2-directed therapy eligibility, radiation oncology management for non-surgical candidates and adjuvant disease settings, and emerging trastuzumab-based and pembrolizumab systemic therapy for advanced and HER2-positive invasive EMPD. Technology failures in any of these areas create disruptions calibrated to the diagnostic classification biology, invisible intraepithelial tumor extent, HER2-directed therapy complexity, and visceral malignancy coordination demands unique to EMPD management.
Dermatopathology platforms coordinate the immunohistochemical workup on which the primary-versus-secondary EMPD classification depends. The clinical and histologic indistinguishability of primary EMPD from secondary pagetoid spread of a visceral adenocarcinoma — where CK20-positive perianal Paget disease should direct toward colonoscopy to exclude synchronous colorectal carcinoma, and where GATA3-positive penile Paget disease should direct toward cystoscopy to exclude synchronous urothelial carcinoma — means that immunohistochemical panel result routing is the first clinical branch point in EMPD management, preceding all surgical, radiation, and systemic therapy decisions with a diagnostic determination whose accuracy defines whether the patient is treated for a primary cutaneous malignancy or a cutaneous manifestation of a visceral cancer. Monitor dermatopathology immunohistochemical panel platforms at 1-minute intervals during business hours.
HER2 molecular diagnostics platforms identify the targetable molecular driver that defines advanced EMPD management. HER2 overexpression and amplification in 50–70% of invasive EMPD — a prevalence substantially higher than in breast or gastric cancer — establishes HER2 FISH amplification testing and HER2 immunohistochemistry (3+ staining or FISH amplification ratio ≥2.0) as standard molecular workup for all invasive EMPD patients, with results directing toward trastuzumab-based therapy (trastuzumab monotherapy, trastuzumab plus pertuzumab, trastuzumab deruxtecan) in the advanced or metastatic disease setting and representing the most actionable molecular biomarker in EMPD management. HER2 FISH result routing, HER2 immunostaining result documentation, and HER2-equivocal (2+) reflex FISH testing platforms cannot fail during active workup for invasive or metastatic EMPD. Monitor HER2 molecular diagnostics platforms at 1-minute intervals during business hours.
Mohs micrographic surgery platforms enable complete margin assessment for intraepithelial EMPD with invisible subclinical extent. The intraepithelial EMPD disease extent beyond the visible erythematous plaque — where Paget cells migrate within the epidermis in a pagetoid pattern that extends centimeters beyond the clinical tumor margin without altering the normal macroscopic appearance of the surrounding anogenital skin — explains the 30–50% local recurrence rate after standard wide excision and establishes Mohs micrographic surgery (using CK7, GCDFP-15, CAM5.2, and androgen receptor immunostaining on frozen sections to identify scattered Paget cells within normal-appearing epidermis at the surgical margin) as the preferred surgical technique for anogenital EMPD where tissue conservation and complete margin evaluation are both critical. Monitor Mohs surgery pathology platforms at 1-minute intervals during active procedural windows.
Visceral malignancy exclusion workup platforms coordinate colonoscopy, cystoscopy, and gynecologic evaluation for secondary EMPD screening. Every patient with newly diagnosed perianal, penile, or vulvar EMPD requires a formal visceral malignancy exclusion workup before surgical planning is finalized — colonoscopy for perianal EMPD to exclude synchronous colorectal adenocarcinoma, cystoscopy for penile and perineal EMPD to exclude urothelial carcinoma, and gynecologic evaluation for vulvar EMPD to exclude endometrial and cervical carcinoma — creating a dependency on gastroenterology, urology, and gynecology procedure scheduling platforms that must integrate with the dermatopathology immunohistochemical result and the treating multidisciplinary team before the surgical plan is confirmed. Monitor visceral exclusion workup coordination platforms at 1-minute intervals during business hours.
Radiation oncology platforms deliver definitive anogenital radiotherapy to non-surgical candidates and adjuvant radiation for invasive disease. Definitive external beam radiation to the vulvar, perianal, or penile anogenital EMPD field — in patients who decline surgery, who have unresectable disease, or for whom the surgical defect would require permanent colostomy or urinary diversion — requires treatment planning with dose-volume constraints for the bowel, bladder, femoral heads, and femoral necks in the anogenital radiation field, a technically demanding geometric and clinical optimization that is site-specific to the anogenital anatomy. Brachytherapy (interstitial or surface-mold brachytherapy) for localized vulvar or perianal EMPD adds an additional procedural coordination requirement. Monitor radiation oncology platforms at 1-minute intervals during business hours and active treatment and brachytherapy procedural sessions.
What to Monitor on a Extramammary Paget Disease Tech Platform
Dermatopathology — Primary vs Secondary EMPD Classification
Monitor EMPD immunohistochemical panel result routing (CK7, CK20, GCDFP-15, CAM5.2, androgen receptor, GATA3, CDX2, AMACR) for primary versus secondary EMPD classification, digital pathology consultation routing for subspecialty expert review of EMPD immunopanels at institutions without in-house cutaneous adenocarcinoma pathology expertise, HER2 immunohistochemistry (1+, 2+, 3+ scoring) result documentation and reflex HER2 FISH ordering for 2+ cases, microsatellite instability immunohistochemistry and MSI-PCR panel result routing for pembrolizumab eligibility assessment, tumor depth measurement and dermis invasion documentation for invasive versus in situ EMPD classification, lymphovascular invasion documentation for staging, and molecular profile result integration into multidisciplinary tumor board records at 1-minute intervals during business hours. Alert immediately — immunohistochemical panel platform failures during active result routing for newly diagnosed EMPD delay the primary-versus-secondary classification that determines whether the patient's management plan begins with colonoscopy and colorectal oncology referral or proceeds directly to EMPD-specific surgical or radiation treatment planning.
HER2 Molecular Diagnostics
Monitor HER2 FISH amplification test ordering and result routing for invasive and metastatic EMPD, HER2 immunostaining result integration and amplification ratio documentation, reflex FISH test result routing for HER2-equivocal (2+) immunostaining cases, trastuzumab eligibility determination records linked to HER2 molecular testing results, HER2 result communication to the treating medical oncologist and multidisciplinary team, and clinical trial eligibility determination records for HER2-positive advanced EMPD at 1-minute intervals during business hours. Alert immediately — HER2 FISH platform failures during active result routing delay the trastuzumab eligibility determination for advanced or metastatic EMPD patients where HER2-directed therapy represents the most rationally targeted systemic option.
Mohs Micrographic Surgery
Monitor Mohs surgery scheduling and tissue map documentation for vulvar, perianal, scrotal, and penile EMPD with intraepithelial disease extent beyond visible margins, intraoperative immunostained frozen section result routing (CK7, GCDFP-15, CAM5.2, androgen receptor, CKMNF116) for Paget cell margin identification in normal-appearing anogenital skin at surgical edges, stage-by-stage defect tracking and peripheral and deep margin documentation, total stage count and final margin clearance documentation including circumferential intraepithelial margin clearance, reconstructive planning initiation records after final margin clearance, multi-disciplinary reconstructive team notification records (gynecologic plastic surgery, colorectal reconstructive surgery, urologic reconstructive surgery), and wound management protocol access during multi-day Mohs procedures for large anogenital EMPD fields at 1-minute intervals during active Mohs procedural windows. Alert immediately during active Mohs stages — immunostaining platform failures during anogenital EMPD Mohs procedures halt the iterative margin assessment that identifies subclinical Paget cell extension in visually normal anogenital skin, and the large surgical defects of anogenital EMPD Mohs procedures cannot be left open indefinitely.
Visceral Malignancy Exclusion Workup Coordination
Monitor colonoscopy scheduling and procedure result routing for perianal EMPD visceral exclusion (colorectal adenocarcinoma), cystoscopy scheduling and result routing for penile and perineal EMPD visceral exclusion (urothelial carcinoma), gynecologic evaluation and endometrial sampling records for vulvar EMPD (endometrial and cervical carcinoma exclusion), upper endoscopy records where gastric or esophageal adenocarcinoma enters the differential for axillary EMPD, visceral malignancy exclusion result integration into EMPD multidisciplinary tumor board records, treatment plan finalization records confirming primary EMPD classification after negative visceral workup, and colorectal or urologic oncology referral records for patients where visceral workup identifies a synchronous visceral malignancy requiring coordinated management at 1-minute intervals during business hours. Alert immediately — visceral exclusion workup coordination platform failures delay the final treatment plan confirmation for EMPD patients whose management cannot be fully committed until the primary versus secondary classification is confirmed by negative visceral malignancy workup.
Gynecologic Oncology — Vulvar EMPD Resection and Reconstruction
Monitor vulvar wide local excision planning and pre-operative anatomic documentation for vulvar EMPD, Mohs-coordinated vulvar resection records with immunostained margin results, vulvar reconstructive surgery planning records (flap design, adjacent tissue rearrangement, skin graft planning for large vulvar defects), sexual function rehabilitation consultation records, pelvic floor physical therapy referral and documentation, sentinel lymph node biopsy records for invasive vulvar EMPD, inguinal lymph node dissection planning and operative records for node-positive disease, post-operative wound care and healing documentation in the anogenital region where wound complications are common, and gynecologic oncology survivorship care records at 1-minute intervals during business hours and operative windows.
Colorectal Surgery — Perianal EMPD Resection and Reconstruction
Monitor perianal and perineal EMPD resection planning records, perianal reconstructive surgery planning and flap design documentation for large perianal EMPD defects, sphincter preservation documentation for perianal EMPD cases adjacent to the anal sphincter complex, colostomy planning records for patients where sphincter involvement requires diversion, colorectal carcinoma coordination records for patients with synchronous colorectal carcinoma requiring coordinated EMPD and colorectal resection, post-operative perianal wound care and healing documentation, and anorectal function assessment records at 1-minute intervals during business hours and operative windows.
Urologic Oncology — Penile and Perineal EMPD
Monitor penile and scrotal EMPD resection planning records and penile-sparing versus glans-conserving surgery documentation, urologic reconstructive surgery planning for penile and scrotal defect coverage, urothelial carcinoma coordination records for patients where cystoscopy identifies a synchronous urothelial primary requiring coordinated EMPD and urothelial malignancy management, post-operative urinary function assessment records, and penile rehabilitation consultation records at 1-minute intervals during business hours and operative windows.
Radiation Oncology — Definitive and Adjuvant Anogenital Radiotherapy
Monitor external beam radiation treatment planning records for vulvar, perianal, and penile anogenital EMPD fields with dose-volume constraints for bowel, bladder, rectum, femoral heads and necks, and clitoris (in vulvar EMPD patients managed with organ-preservation radiation intent), interstitial and surface-mold brachytherapy planning and delivery records for localized EMPD, IMRT and VMAT plan optimization for anogenital fields, radiation-induced acute and late toxicity surveillance documentation (radiodermatitis, moist desquamation, anal stenosis, urinary toxicity, sexual function impairment), and adjuvant radiation records for invasive EMPD with lymph node involvement or high-risk surgical pathology at 1-minute intervals during business hours and active treatment and brachytherapy procedural sessions.
Medical Oncology — HER2-Directed Therapy and Immunotherapy
Monitor trastuzumab dosing and infusion records for HER2-positive invasive or metastatic EMPD, pertuzumab combination dosing records, trastuzumab deruxtecan (T-DXd) dosing and interstitial lung disease surveillance records (a critical pulmonary toxicity requiring early CT chest surveillance and treatment interruption at grade 1 ILD), lapatinib dosing and hepatotoxicity surveillance records, pembrolizumab dosing and immune-related adverse event records for MSI-H or PD-L1-positive EMPD, cardiac function surveillance records including echocardiographic LVEF monitoring for trastuzumab-related cardiotoxicity, clinical trial enrollment and protocol therapy records for advanced EMPD, and response assessment imaging documentation at 1-minute intervals during business hours and active infusion sessions. Alert immediately during active trastuzumab, T-DXd, or pembrolizumab infusion sessions.
Long-Term Surveillance and Dermatologic Follow-Up
Monitor long-term anogenital skin surveillance appointment scheduling (EMPD local recurrence rates of 30–50% demand frequent follow-up skin examinations of the entire anogenital field, with vulvar, perianal, penile, and axillary sites examined at 3–6 month intervals indefinitely), local recurrence assessment and biopsy records, surveillance colonoscopy and cystoscopy scheduling for patients with prior secondary EMPD exclusion workup requiring ongoing visceral surveillance, re-treatment planning records for recurrent in situ EMPD (imiquimod, photodynamic therapy, repeat Mohs surgery, or radiation), and referral records to specialist dermatologic oncology programs for multiply recurrent or refractory EMPD at 2-minute intervals during business hours.
Imiquimod and Topical Therapy Management
Monitor imiquimod topical therapy prescribing and patient education records for in situ EMPD patients managed non-surgically, treatment response assessment and clinical examination documentation (imiquimod response rates of 50–60% for in situ EMPD in published series), toxicity monitoring records for imiquimod-induced inflammatory reactions and erosion at the anogenital application site, treatment interruption and dose modification records, and transition-to-surgery records for patients with incomplete imiquimod response at 2-minute intervals during business hours.
Multidisciplinary Tumor Board Coordination
Monitor EMPD multidisciplinary tumor board case presentation records spanning gynecologic oncology, colorectal surgery, urologic oncology, dermatologic oncology, radiation oncology, molecular pathology, and medical oncology, imaging and pathology synchronization between multiple programs (including visceral malignancy exclusion workup results, HER2 FISH results, and immunohistochemical EMPD panel results), Mohs surgery coordination records for complex anogenital cases, reconstructive surgery planning integration records, referral records to specialist EMPD programs, and treatment modification records at 1-minute intervals during business hours.
Patient Communication Portal
Monitor patient portal availability for anogenital wound care communication and dressing guidance during post-operative healing in the complex anogenital wound environment, radiation-induced radiodermatitis and moist desquamation symptom reporting during active anogenital radiation treatment, trastuzumab and T-DXd adverse effect symptom reporting (dyspnea, cough for ILD surveillance; cardiac symptoms for trastuzumab cardiotoxicity; nausea, alopecia for systemic therapy toxicity), imiquimod application site reaction reporting and dose modification guidance communication, sexual health and rehabilitation consultation coordination, long-term surveillance appointment management across multiple anogenital oncology subspecialties, and care team secure messaging. Alert on sustained failures — anogenital radiation toxicity and T-DXd-associated ILD symptoms require rapid clinical assessment, and portal failures during active treatment may delay identification of toxicities requiring urgent intervention.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. EMPD programs coordinate across dermatopathology, Mohs surgery, gynecologic oncology, colorectal surgery, urologic oncology, radiation oncology, gastroenterology, urology, medical oncology, sexual health rehabilitation, and dermatology — authentication failures simultaneously block the entirety of a multispecialty team managing a malignancy whose diagnostic, surgical, radiation, and systemic therapy complexity spans multiple disease programs with different institutional home departments.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across all patient portals, surgical planning systems, radiation oncology interfaces, dermatopathology platforms, HER2 molecular diagnostics systems, immunotherapy management platforms, visceral malignancy exclusion workup coordination tools, and long-term surveillance scheduling systems.
HIPAA and Oncology Data Privacy Considerations
Extramammary Paget disease technology platforms handle PHI of exceptional sensitivity given the anogenital anatomic location of this malignancy: operative records from vulvar, perianal, and penile resection and reconstruction that document permanent anatomic and functional alterations to the genitalia and anus, including changes to sexual function and continence that carry profound personal significance and that patients may be deeply reluctant to have disclosed; radiation oncology treatment records for anogenital irradiation with dose-volume documentation for fertility structures (ovaries, uterus in women of reproductive age undergoing vulvar EMPD radiation) that may have implications for reproductive potential; sexual health rehabilitation records documenting sexual dysfunction, lubricant use, and pelvic floor therapy that patients may consider among their most private health information; HER2 molecular testing and immunotherapy records with treatment response documentation for a rare anogenital malignancy; and long-term surveillance records documenting recurrent anogenital skin examinations over decades of follow-up. HIPAA Security Rule requirements for PHI availability and integrity apply with particular force to the patient portal and secure messaging platforms where patients with anogenital malignancy communicate about wound healing, sexual rehabilitation, and surveillance findings — topics where patients may be uniquely reluctant to seek clinical support if portal security is in any way uncertain.
For platforms managing anogenital radiation oncology records for women of reproductive age undergoing vulvar EMPD irradiation — where ovarian function, fertility potential, and menopausal timing are affected by the radiation dose received by the ovaries and where documentation of ovarian transposition (oophoropexy) or fertility preservation decisions is part of the treatment record — availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for programs managing oncology PHI that intersects with reproductive health in a population where the implications of treatment on future fertility and hormonal health extend across decades.
Alerting Strategy for Extramammary Paget Disease Tech Platforms
Immediate alerting 24/7: Authentication and core platform access. EMPD patients on active trastuzumab, T-DXd, or pembrolizumab therapy may require urgent care team access outside business hours for management of T-DXd-associated ILD, trastuzumab infusion reactions, or immune-related adverse events from pembrolizumab.
Immediate alerting during treatment sessions: Medical oncology platforms during active trastuzumab, T-DXd, and pembrolizumab infusion sessions; radiation oncology platforms during active anogenital external beam and brachytherapy treatment sessions.
Immediate alerting during operative and procedural windows: Mohs micrographic surgery pathology platforms during active Mohs stages; gynecologic, colorectal, and urologic surgical oncology platforms during operative sessions.
Immediate business-hours alert: Dermatopathology immunohistochemical panel platforms (primary versus secondary EMPD classification), HER2 molecular diagnostics (trastuzumab eligibility), visceral malignancy exclusion workup coordination (colonoscopy, cystoscopy result integration), and multidisciplinary tumor board coordination. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Long-term anogenital surveillance scheduling, patient communication portal, imiquimod therapy monitoring platforms, sexual health rehabilitation coordination, and post-treatment imaging scheduling.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms EMPD platform availability from the geographies where gynecologic oncology, colorectal surgery, urologic oncology, Mohs surgery, radiation oncology, and medical oncology programs access the system — important for the geographically distributed multispecialty team managing a rare anogenital malignancy that frequently requires specialist center involvement for complex Mohs surgery, anogenital reconstructive surgery, and HER2-directed systemic therapy.
Status Page for Extramammary Paget Disease Care Team Communication
A real-time status page gives gynecologic oncologists coordinating vulvar resection and reconstruction, colorectal surgeons managing perianal EMPD, urologic oncologists managing penile EMPD, Mohs surgeons performing intraoperative immunostained margin assessment, radiation oncologists delivering anogenital radiotherapy, molecular pathologists routing HER2 FISH and immunohistochemical panel results, gastroenterologists and urologists completing visceral malignancy exclusion workup, medical oncologists managing trastuzumab and T-DXd therapy, and tumor board coordinators immediate platform visibility without requiring inbound IT support contact. During a Mohs pathology platform outage during an active anogenital EMPD Mohs procedure where CK7 immunostaining of stage 4 tissue is in process, a status page enables immediate notification of the treating surgeon and reconstructive surgery team before the platform failure forces a wound management decision that should have been preceded by margin clearance confirmation.
Include the status page URL in Mohs surgery pathology downtime procedures, anogenital radiation oncology emergency protocols, T-DXd ILD management protocols requiring urgent platform access, visceral workup coordination fallback workflows, and immunotherapy management emergency procedures.
Vigilmon Setup for Extramammary Paget Disease Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Dermatopathology — CK7 / CK20 / GCDFP-15 panel (business hours) | 1 min | Slack + PagerDuty (business hours) | | HER2 molecular diagnostics — FISH and IHC (business hours) | 1 min | Slack + PagerDuty (business hours) | | Mohs micrographic surgery pathology (procedural hours) | 1 min | Slack + PagerDuty (procedural hours) | | Visceral malignancy exclusion workup coordination (business hours) | 1 min | Slack + PagerDuty (business hours) | | Gynecologic oncology / vulvar surgery (operative hours) | 1 min | Slack + PagerDuty (operative hours) | | Colorectal surgery / perianal resection (operative hours) | 1 min | Slack + PagerDuty (operative hours) | | Urologic oncology / penile EMPD (operative hours) | 1 min | Slack + PagerDuty (operative hours) | | Radiation oncology — anogenital irradiation (treatment hours) | 1 min | Slack + PagerDuty (treatment hours) | | Trastuzumab / T-DXd / pembrolizumab management (infusion sessions) | 1 min | Slack + PagerDuty (treatment hours) | | Multidisciplinary tumor board coordination | 1 min | Slack + PagerDuty (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | Long-term anogenital surveillance scheduling | 2 min | Slack (business hours) | | Imiquimod topical therapy monitoring | 2 min | Slack (business hours) | | Post-treatment imaging scheduling | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure dermatopathology immunohistochemical panel platforms with immediate business-hours alerting for CK7/CK20/GCDFP-15/GATA3/androgen receptor primary versus secondary EMPD classification result routing
- Add HER2 molecular diagnostics (FISH amplification and IHC scoring) with immediate business-hours alerting for trastuzumab eligibility determination
- Configure Mohs micrographic surgery pathology platforms with immediate alerting during active anogenital EMPD Mohs procedural hours including CK7/CAM5.2 immunostaining processing windows
- Add visceral malignancy exclusion workup coordination (colonoscopy, cystoscopy, gynecologic evaluation result integration) with immediate business-hours alerting
- Configure site-specific surgical oncology platforms (gynecologic, colorectal, urologic) with immediate alerting during operative windows
- Add radiation oncology treatment planning and delivery platforms with immediate alerting during active anogenital external beam and brachytherapy sessions
- Configure medical oncology platforms for trastuzumab, pertuzumab, trastuzumab deruxtecan (T-DXd), lapatinib, and pembrolizumab with immediate alerting during active infusion sessions and T-DXd ILD surveillance workflows
- Add multidisciplinary tumor board coordination across gynecologic oncology, colorectal surgery, urologic oncology, dermatologic oncology, and medical oncology tumor board programs with immediate alerting during scheduled sessions
- Configure patient communication portal monitoring for anogenital wound care communication, radiation toxicity symptom reporting, T-DXd pulmonary symptom reporting, and sexual health rehabilitation coordination
- Add long-term anogenital surveillance scheduling with sustained-failure alerting reflecting the lifetime surveillance requirement for a disease with 30–50% local recurrence rates
- Configure imiquimod topical therapy monitoring with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, patient-facing, pathology, HER2 molecular diagnostics, radiation oncology, and systemic therapy management domains, and add the status page URL to Mohs pathology downtime procedures, anogenital radiation emergency protocols, T-DXd ILD management protocols, and immunotherapy fallback workflows
Conclusion
Extramammary Paget disease technology platforms are embedded in clinical decisions where dermatopathology immunohistochemical panel platform availability during CK20 and GATA3 result routing for a newly diagnosed perianal EMPD patient determines whether the treating team receives the immunostaining result showing CK20 positivity and CDX2 expression that classifies the case as secondary EMPD consistent with colorectal adenocarcinoma pagetoid spread — immediately initiating colonoscopy scheduling, colorectal oncology referral, and PET-CT staging for a patient who had been planned for Mohs surgery as a primary EMPD patient until the immunopanel result redirected the management pathway to visceral malignancy evaluation — where HER2 molecular diagnostics platform availability during FISH amplification result routing for a patient with invasive EMPD of the vulva with inguinal lymph node metastases determines whether the medical oncologist can access the HER2 FISH amplification ratio confirming HER2-positive status with a ratio of 4.2 that establishes the patient's eligibility for trastuzumab plus pertuzumab combination therapy as first-line treatment for metastatic disease, a treatment decision that cannot be confirmed until the HER2 molecular result is accessible in the treatment planning platform — and where Mohs surgery pathology platform availability during stage 5 immunostaining processing for a large perianal EMPD Mohs case determines whether the CK7 immunostain showing residual scattered Paget cells at the posterior deep margin can be routed to the Mohs surgeon who is waiting with the patient in the procedure room to decide whether a sixth tissue stage is needed before reconstruction of the perianal defect can be planned, a decision that cannot be delegated or deferred without the immunostained frozen section result that is the only reliable method for detecting invisible intraepithelial Paget cell extension in the perianal skin at the margin of a large surgical defect. A dermatopathology panel platform unavailable for three hours during the result routing of the primary-versus-secondary EMPD immunopanel for a patient with newly diagnosed perianal Paget disease does not merely delay a pathology report: it delays the clinical branch-point determination between a primary EMPD surgical treatment pathway and a secondary EMPD visceral malignancy evaluation pathway, during which the treating team cannot schedule Mohs surgery (inappropriate if the lesion is secondary EMPD from a colorectal primary requiring systemic therapy first), cannot initiate colonoscopy referral (inappropriate if the lesion is primary EMPD not associated with colorectal carcinoma), and cannot present the case at tumor board with a confirmed diagnosis — leaving the multidisciplinary team in diagnostic limbo for the duration of the platform outage. A T-DXd management platform unavailable during the clinic visit of a patient on trastuzumab deruxtecan for HER2-positive metastatic vulvar EMPD who presents with new-onset cough and dyspnea requires the oncologist to manage a potential grade 1 interstitial lung disease presentation — the most feared pulmonary toxicity of T-DXd, requiring treatment interruption at grade 1 and permanent discontinuation at grade 2 or higher — without access to the prior T-DXd cycle records, the baseline pulmonary function documentation, and the institutional ILD management protocol that specifies the CT chest ordering criteria, corticosteroid dosing, and pulmonologist consultation threshold that defines the clinical management of this serious and potentially fatal adverse effect.
Uptime monitoring gives EMPD tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to gynecologic oncology, colorectal surgery, urologic oncology, Mohs surgery, radiation oncology, medical oncology, and compliance auditors that the platform's operational reliability matches the immunohistochemical primary-versus-secondary diagnostic precision, HER2-directed therapy management complexity, Mohs surgery intraepithelial margin assessment requirements, anogenital radiation planning intricacy, and visceral malignancy exclusion coordination demands of modern extramammary Paget disease care.
Start monitoring your extramammary Paget disease tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #extramammarypagetdisease #EMPD #vulvarcancer #perinalcancer #penilecancer #HER2 #trastuzumab #trastuzumabderuxtecan #mohssurgery #dermatopathology #anogenitaloncology #gynecologiconcology #immunotherapy #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre